Bringing the very best science and medicine to our best equine friends

NEWS

Kindred Biosciences Announces Initiation of Pilot Field Study of Atopic Dermatitis and Other Updates

San Francisco, CA (June 14, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced the initiation of a pilot field study designed to test several molecules, including anti-cytokine antibodies, in dogs with atopic dermatitis. The pilot field study in dogs with atopic dermatitis is a multi-center pilot study to assess safety and efficacy of several molecules, and to determine the candidate(s) that will be taken into further development. In addition, KindredBio provided an update on its equine biologics program. The first stage of a pilot field study in sick or …

Continue Reading

World’s Top Show Jumper, McLain Ward, wins the $15,000 KindredBio Jumper Prix

Saugerties, NY (June 12, 2016) The HITS-on-the-Hudson III at the Grand Prix Stadium saw some excellent competition on Saturday and we were excited to see the action around the $15,000 KindredBio 1.40M Jumper Prix. McLain Ward, a two-time Olympic gold medalist and currently ranked the #1 show jumper in the world, aboard Best Buy, a nine-year-old Holsteiner mare owned by Double H Farm, topped the competition. The team was clean in the first round along with 8 other horse and rider combinations.  Ward and Best Buy had a fast and clean jump-off round, navigating the tough track in a fast …

Continue Reading

Kindred Biosciences Announces HITS Sponsorship

San Francisco, CA (May 25, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, is pleased to announce their Platinum Sponsorship of the HITS Horse Show series.  The sponsorship will start this week at the Saugerties, New York facility for the HITS-on-the-Hudson series and will extend through both the HITS Ocala Winter Circuit in Ocala, Florida, and the HITS Desert Circuit in Thermal, California. Denise Bevers, Co-Founder and Chief Operating Officer, said, “As a company dedicated to developing innovative medications for our horse companions, we are very pleased to be partnering …

Continue Reading

Kindred Biosciences Announces First Quarter 2016 Financial Results

San Francisco, CA (May 5, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2016 and provided updates on its programs. “We successfully advanced our lead product candidates in the first quarter. We look forward to reporting topline results for KIND-010, a transdermal gel for the management of weight loss in cats, by mid-year, as planned. Additionally, preparations for the commercial launch of Zimeta for fever in horses are on track, positioning KindredBio for the expected revenue generation by the …

Continue Reading

Kindred Biosciences to Announce First Quarter 2016 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Thursday, May 5, 2016 San Francisco, CA (April 25, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its first quarter 2016 financial results on May 5, 2016 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day. Interested parties may access the call by dialing toll-free (855) 433-0927 from the US, or (484) …

Continue Reading

Kindred Biosciences Elects Herbert D. Montgomery to Join Its Board of Directors

Highly Experienced Finance Executive to Join KindredBio’s Board San Francisco, CA (April 15, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Mr. Herbert Montgomery will be joining the Company’s Board of Directors.  Mr. Montgomery will serve as the Chairman of the Company’s Audit Committee. Mr. Montgomery has extensive experience in finance, including having served as CFO of several public companies, and having taken three companies public.  Most recently, he was Vice Chairman of the Board and Executive Officer of Lightpost Holdings, LLC. Prior to that, Mr. Montgomery …

Continue Reading

PRESS RELEASE – Kindred Biosciences Submits Final Major New Animal Drug Application Technical Section for Safety for Zimeta to FDA

San Francisco, CA (March 15, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Safety technical section of the New Animal Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  This is the final major technical section to be submitted for Zimeta. The Chemistry, Manufacturing, and Controls technical section was submitted in December 2015 and the Effectiveness technical section was submitted in February 2016. In the target animal safety study, Zimeta, was well tolerated with no clinically-significant changes when compared to control horses (placebo ...
Continue Reading